Literature DB >> 18472197

Structured treatment interruptions (STIs) in HIV-1 infected pediatric populations increases interferon gamma production and reduces viremia.

William Borkowsky1, Ram Yogev, Petronella Muresan, Elizabeth McFarland, Lisa Frenkel, Terry Fenton, Edmond Capparelli, Jack Moye, Paul Harding, Nina Ellis, Barbara Heckman, Joyce Kraimer.   

Abstract

We assessed the effect of progressively longer antiretroviral structured treatment interruptions (STIs) starting with 3 days, increasing by 2 days in length each cycle on HIV-specific immune responses. As well, we correlated these responses with control of HIV viremia. Eight individuals became viremic and reached cycle 13 with an STI of > or =27 days. HIV-specific gamma-interferon production to inactivated HIV and vaccinia vectors expressing gag, env, nef, and pol increased (>10-fold) in six of eight subjects. Median plasma RNA levels peaked @ cycle 7 and declined to levels <10(4)cp/ml after cycle 10. In a subset of five who reached cycle 17, HIV-specific IFN-gamma frequencies increased from cycle 8 to cycle 17 with evidence of improved virologic control over comparable periods off antiretroviral therapy. This allowed us to conclude that exposure to autologous virus increased HIV-specific immune responses and decreased HIV RNA were seen in those who have had >13 interruptions, with STI intervals that exceeded 27 days.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18472197      PMCID: PMC3643503          DOI: 10.1016/j.vaccine.2007.12.017

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  24 in total

1.  Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization.

Authors:  Anne-Marte B Kran; Maja A Sommerfelt; Birger Sørensen; Jørgen Nyhus; Ingebjørg Baksaas; Johan N Bruun; Dag Kvale
Journal:  Vaccine       Date:  2005-04-07       Impact factor: 3.641

2.  Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.

Authors:  L Ruiz; J Martinez-Picado; J Romeu; R Paredes; M K Zayat; S Marfil; E Negredo; G Sirera; C Tural; B Clotet
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

3.  Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.

Authors:  Jeffrey M Jacobson; R Pat Bucy; John Spritzler; Michael S Saag; Joseph J Eron; Robert W Coombs; Rui Wang; Lawrence Fox; Victoria A Johnson; Susan Cu-Uvin; Susan E Cohn; Donna Mildvan; Dorothy O'Neill; Jennifer Janik; Lynette Purdue; Deborah K O'Connor; Christine Di Vita; Ian Frank
Journal:  J Infect Dis       Date:  2006-08-01       Impact factor: 5.226

4.  The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.

Authors:  F García; M Plana; G M Ortiz; S Bonhoeffer; A Soriano; C Vidal; A Cruceta; M Arnedo; C Gil; G Pantaleo; T Pumarola; T Gallart; D F Nixon; J M Miró; J M Gatell
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

5.  Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094).

Authors:  Roland Tubiana; Guislaine Carcelain; Muriel Vray; Karine Gourlain; Cécile Dalban; Aziza Chermak; Claire Rabian; Daniel Vittecoq; Anne Simon; Elisabeth Bouvet; Raphaelle El Habib; Dominique Costagliola; Vincent Calvez; Brigitte Autran; Christine Katlama
Journal:  Vaccine       Date:  2005-07-29       Impact factor: 3.641

6.  Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.

Authors:  Ellen Harrer; Michael Bäuerle; Barbara Ferstl; Paul Chaplin; Barbara Petzold; Luis Mateo; Amanda Handley; Maria Tzatzaris; Jens Vollmar; Silke Bergmann; Marion Rittmaier; Kathrin Eismann; Sandra Müller; Joachim R Kalden; Bernd Spriewald; Dieter Willbold; Thomas Harrer
Journal:  Antivir Ther       Date:  2005

7.  Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption.

Authors:  E Papasavvas; G M Ortiz; R Gross; J Sun; E C Moore; J J Heymann; M Moonis; J K Sandberg; L A Drohan; B Gallagher; J Shull; D F Nixon; J R Kostman; L J Montaner
Journal:  J Infect Dis       Date:  2000-08-17       Impact factor: 5.226

8.  Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.

Authors:  G Carcelain; R Tubiana; A Samri; V Calvez; C Delaugerre; H Agut; C Katlama; B Autran
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

9.  Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators.

Authors:  W Borkowsky; D Wara; T Fenton; J McNamara; M Kang; L Mofenson; E McFarland; C Cunningham; A M Duliege; D Francis; Y Bryson; S Burchett; S A Spector; L M Frenkel; S Starr; R Van Dyke; E Jimenez
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

10.  Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection.

Authors:  M Altfeld; E S Rosenberg; R Shankarappa; J S Mukherjee; F M Hecht; R L Eldridge; M M Addo; S H Poon; M N Phillips; G K Robbins; P E Sax; S Boswell; J O Kahn; C Brander; P J Goulder; J A Levy; J I Mullins; B D Walker
Journal:  J Exp Med       Date:  2001-01-15       Impact factor: 14.307

View more
  2 in total

Review 1.  Antiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi baby.

Authors:  Stephanie Shiau; Louise Kuhn
Journal:  Expert Rev Anti Infect Ther       Date:  2014-02-09       Impact factor: 5.091

2.  The immunological and virological consequences of planned treatment interruptions in children with HIV infection.

Authors:  Nigel Klein; Delali Sefe; Ilaria Mosconi; Marisa Zanchetta; Hannah Castro; Marianne Jacobsen; Hannah Jones; Stefania Bernardi; Deenan Pillay; Carlo Giaquinto; A Sarah Walker; Diana M Gibb; Anita De Rossi
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.